** Shares of Gyre Therapeutics GYRE.O down 15.3% before the bell to $9.50 after follow-on priced
** San Diego-based biotech late Thurs announced ~2.2 mln shares at $9 for $20 mln gross proceeds
** Offering price represents 19.7% discount to stock's last sale
** Co intends to use net proceeds to fund advancement of its Phase II trial of F351 in metabolic dysfunction-associated steatohepatitis ("MASH”)-associated liver fibrosis in the U.S., for R&D, and manufacturing among other purposes
** Jefferies is bookrunner for offering
** Late Thurs, co said its lead compound, Hydronidone (F351), met primary endpoint in pivotal Phase III trial evaluating efficacy and safety for treatment of fibrosis in patients with chronic hepatitis B in China
** With ~93.8 mln shares outstanding as of May 1, co has ~$1bln market cap
** GYRE shares on Thurs rose 8.1% to $11.21, trimming YTD loss to ~7%
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。